Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: A global developer and manufacturer of minimally invasive medical devices, with a primary focus on interventional cardiology (notably the TAXUS drug-eluting stent system), electrophysiology, neurovascular, and endoscopy. The period was characterized by significant revenue growth driven by the U.S. launch of the TAXUS stent and major acquisitions (Advanced Bionics and Precision Vascular Systems).
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 | 3 Months Ended Sep 30, 2003 | 9 Months Ended Sep 30, 2003 |
|---|---|---|---|---|
| Net Sales | $1,482 | $4,024 | $876 | $2,537 |
| Gross Profit | $1,173 | $3,060 | $633 | $1,833 |
| Gross Margin % | 79.1% | 76.0% | 72.3% | 72.3% |
| Operating Income | $358 | $1,070 | $173 | $501 |
| Net Income | $258 | $765 | $124 | $335 |
| Diluted EPS | $0.30 | $0.89 | $0.15 | $0.40 |
| Cash from Operations (9mo) | $1,147 | $553 | ||
| Total Debt (Gross) | $2,496 | $1,725 | ||
| Cash & Equivalents | $1,105 | $671 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 69% year-over-year for the quarter and 59% for the nine-month period. Growth was primarily driven by $640 million in TAXUS stent sales for the quarter and $1,453 million for the nine months.
- Profitability: Net income doubled for the quarter (108% increase) and more than doubled for the nine-month period (128% increase). Gross margins expanded significantly (approx. 640-720 basis points) due to a favorable product mix shift toward higher-margin drug-eluting stents.
- Acquisitions: Completed acquisitions of Advanced Bionics ($740 million initial payment) and Precision Vascular Systems ($75 million initial payment), resulting in significant purchased R&D charges ($33 million for the quarter, $64 million for the nine months) and increased amortization.
- Debt Structure: Gross debt increased to $2.5 billion from $1.7 billion to fund acquisitions and operations. The company refinanced credit facilities to $2.02 billion and issued $600 million in senior notes due 2014.
Guidance, Outlook, Risks, and Unusual Items
Unusual Items & Charges
- Legal Provision: Recorded a $75 million pre-tax charge in Q3 2004 for legal and regulatory exposures, increasing total litigation accruals to $97 million.
- Retirement Plan Enhancement: Recorded a $110 million pre-tax charge ($71 million after-tax) to enhance the 401(k) retirement plan.
- Product Recalls: Voluntary recalls of TAXUS and Express(2) stent systems resulted in a $43 million inventory write-down (recorded in Q2) and a $35 million sales returns reserve (reversed in Q3 upon replacement). A separate recall of Advanced Bionics cochlear implants occurred in Q3 with no material financial impact.
Outlook & Management Commentary
- Market Position: Management estimates the 2004 worldwide coronary stent market will approach $4.7 billion. The company expects to maintain leadership but anticipates revenue and earnings growth will normalize to historical levels beginning in Q2 2005.
- Japan Launch: The launch of the TAXUS stent in Japan is delayed to the second half of 2006 pending a small clinical trial with Ticlid therapy.
- Share Repurchase: Board approved a new authorization to repurchase up to 50 million shares; approximately 6 million shares were repurchased in October 2004 for ~$200 million.
Risks & Contingencies
- Litigation: Ongoing complex patent litigation with Johnson & Johnson, Medtronic, and Medinol Ltd. regarding stent technologies. Adverse outcomes could limit sales or reduce margins.
- Regulatory: U.S. Department of Justice investigation regarding the 1998 NIR ON Ranger stent recall remains open; statute of limitations extended into early 2005.
- Competition: Increased competition in the drug-eluting stent market is expected in 2005 (international) and 2006 (U.S.), potentially impacting market share and pricing.
- Contingent Consideration: Estimated maximum potential future contingent consideration for acquisitions is approximately $3.2 billion, dependent on performance milestones through 2013.
Investor Verification Checklist
- Legal Exposure: Verify the status of the $75 million legal provision and the outcomes of pending trials with Johnson & Johnson and Medtronic scheduled for early 2005.
- Recall Resolution: Confirm that the FDA has approved the manufacturing modifications for TAXUS stents and that inventory levels are sufficient to meet demand without further disruption.
- Japan Strategy: Monitor the timeline for the required clinical trial in Japan and the impact of competitor drug-eluting stent launches on market share in that region.
- Acquisition Integration: Assess the progress of integrating Advanced Bionics and the realization of value from the $64 million in purchased R&D charges.
- Debt Maturity: Review the company's plan to refinance the $500 million senior notes due in March 2005 and the $1.1 billion of short-term obligations expected to remain outstanding beyond 12 months.